Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROME
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsPSA and beyond: alternative prostate cancer biomarkersPotential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerComprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countriesBiomarkers in prostate cancer: what's new?Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureCurrent early diagnostic biomarkers of prostate cancerCorrelation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.The Prostate Health Index: a new test for the detection of prostate cancer.Recent progress and perspectives on prostate cancer biomarkers.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations.Biomarkers in localized prostate cancer.Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.Clinical Utility of Biomarkers in Localized Prostate Cancer.Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical ApplicationThe role of prostate cancer biomarkers in undiagnosed men.The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA iPredictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA rangeSignificance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men.Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate CancerTargeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.Prostate cancer: Prostate Health Index--improving screening in men with family history.Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting.Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.Prostate cancer in Asia: A collaborative report.
P2860
Q26750672-9A65080F-19CD-4D99-93A0-8B65E2E17F78Q26770646-2570B7F4-71B7-4146-9687-DA27146753F0Q26784517-6765EF54-DE71-43CA-B0A5-3D10A3BA32EDQ26996461-6228E819-1CC3-498C-9A97-25000C7E3973Q27026210-9CD41DB7-5603-478F-9A41-E09D35AE07ABQ30843223-1DA7AC4F-BB53-44A7-9E52-3B44E78F42F9Q33911725-A7EDAB6D-6927-47D4-9CCF-6C43FC67DEDCQ33922390-D72CA85B-CFB9-4771-880E-FCDE3406AEA0Q34294898-AE5B8632-DB38-41C9-81AB-979FAB53475CQ36970387-33933702-7A4D-4004-BB21-47C26A4C28F1Q37619016-D49AEE6D-96A7-4DE5-B6C3-2B6CE0E31354Q37736079-3228A1A5-74AE-437B-B88E-E15B020CC84CQ37738370-DB102442-9B39-4BEF-8B27-D319DA67788FQ38165242-0AD85FDD-DE98-4FCF-9143-060096582621Q38211603-A7265EDA-0CC8-49C4-A68E-07704C5CA898Q38241107-E1CA1B0B-642D-4985-BD89-839FF3906324Q38258595-BA3DC8AB-D78F-4924-A5E4-2FBECF650FAFQ38697114-679AFEDB-42FD-4A2A-8479-06CED3B877A1Q38762709-E778987C-9AF5-4D1F-83E1-099212199BCBQ38792354-45EEB70C-4010-462D-A4F7-9A960473652CQ38967490-3F34710B-AF34-4CBF-886D-5212D228E845Q39140686-F8031589-5B63-4CE1-9F0B-50934DA76622Q40267154-F8436128-3616-4A7B-A8D7-FA970F404DB6Q40438258-90E90F2E-6E33-4DAA-900D-A5BC75CD4D0DQ40680840-0AD4D026-9896-4A26-AC75-23989F151A3BQ40993267-A17C9E87-9EB9-4354-822A-331010D9E46DQ41191641-E7F5FF5E-EA44-4259-AD5F-6406AABD053FQ42151262-705B2DC3-EE65-4253-A498-8FA2BB496BE1Q47436741-CC015E3D-CB00-45B2-B39B-17744329FDBBQ47794897-BF485A45-FEB2-4DCE-8460-296D4378DAB6Q48328454-DF0EFCB6-665E-4C1C-9CDD-C5E4FE295A1BQ51781558-677ABA73-FE34-4BFE-A79D-8772FA91B05AQ52679257-BD1DA6E7-88E6-418B-98FD-A007A17A25A2Q53570258-1B138297-7B22-4229-88BC-3F6A85E722CEQ55216204-4240088F-25BC-4EDB-A04A-8876E86455AA
P2860
Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROME
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Clinical performance of serum ...... ntre European study, the PROME
@en
Clinical performance of serum ...... ntre European study, the PROME
@nl
type
label
Clinical performance of serum ...... ntre European study, the PROME
@en
Clinical performance of serum ...... ntre European study, the PROME
@nl
prefLabel
Clinical performance of serum ...... ntre European study, the PROME
@en
Clinical performance of serum ...... ntre European study, the PROME
@nl
P2093
P2860
P50
P356
P1433
P1476
Clinical performance of serum ...... study, the PROMEtheuS project
@en
P2093
Alberto Breda
Alexander Haese
Alexandre de la Taille
Andrea Cestari
Giuliana Lista
Jacques Roux
Joan Palou Redorta
Linda Fowler
Markus Graefen
Nicolòmaria Buffi
P2860
P304
P356
10.1111/BJU.12217
P50
P577
2013-08-01T00:00:00Z